CTNNB1 mutations are thought to characterize the immune‐excluded class of hepatocellular carcinoma and may be a biomarker for predicting resistance to immune checkpoint inhibitors.23 This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.